Evidence map›Paper›PMID 42277241›Full record

ArticleScientific reports2026

A lightweight ResNet50V2-ECA model for renal cell carcinoma grading: efficiency, calibration, and state-of-the-art performance.

Majed Alwateer

Abstract read
In one paragraph

Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

Majed AlwateerDepartment of Computer Science, College of Computer Science and Engineering, Taibah University, Yanbu, 46421, Saudi Arabia. mwateer@taibahu.edu.sa.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Accurate International Society of Urological Pathology (ISUP)-grade classification of renal cell carcinoma (RCC) is challenging due to subtle histopathological variations and the limitations of manual review. Existing deep learning models often rely on complex attention mechanisms that increase computational cost and hinder deployment. This study introduces a lightweight ResNet50V2-ECA framework that adds a single Efficient Channel Attention block after the final convolutional layer, enhancing channel-wise discrimination with minimal overhead (0.25 M parameters, 3.1 GFLOPs). Placing a single ECA block before GAP allows global channel recalibration after spatial feature extraction, avoiding the computational redundancy of multi-stage attention while preserving spatial resolution. Using the KMC kidney histopathology dataset (722 WSIs, 3,442 training patches across five grades), the model achieves 96.90% accuracy, 91.39% F1-score, and near-perfect AUC scores (Grade-0: 1.000; Grade-4: 0.997) across standard metrics (accuracy, precision, recall, F1, specificity, BAC, AUC). A comprehensive ablation study across five attention mechanisms (BAM, CBAM, SE, GC, ECA) and three backbones confirms that ResNet50V2-ECA yields the highest overall performance. Comparative analysis with leading RCC frameworks (RoCNN, EFF-Net, RCCGNet, RenalNet, MobileDANet) further demonstrates superior accuracy and efficiency. Model reliability is validated through a calibration diagram using Monte Carlo Dropout, showing strong alignment between predicted confidence and actual accuracy, while the risk-coverage curve reveals accuracy exceeding 99% when low-confidence cases are deferred. Together, these findings establish a high-precision, well-calibrated RCC grading system with strong potential for clinical deployment. While results indicate strong potential for clinical deployment, external multi-center validation is required to confirm generalizability.

Indexed as

Carcinoma, Renal CellDeep LearningKidney NeoplasmsCalibrationConvolutional Neural NetworksHumansNeoplasm GradingAutomated diagnosisDeep Learning (DL)Efficient channel attentionHistopathologyInternational Society of Urologic Pathologists (ISUP) GradingRenal cell carcinomaResNet50V2

Identifiers

PMID42277241
PMCPMC13503756

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.